Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GRPH

Graphite Bio (GRPH) Stock Price, News & Analysis

Graphite Bio logo

About Graphite Bio Stock (NASDAQ:GRPH)

Key Stats

Today's Range
$3.05
$3.23
50-Day Range
$3.18
$26.11
52-Week Range
$2.01
$4.26
Volume
328,300 shs
Average Volume
282,405 shs
Market Capitalization
$185.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Stock News Headlines

CarbonScape plans to build biographite plant in Finland
Versant Vantage II, L.P.'s Net Worth
I've got news for you…
Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week
GRPH Mar 2024 5.000 put
VERI, STI and VERB among mid-day movers
GRPH Mar 2024 7.500 call
Graphite Bio, Inc. (GRPH)
See More Headlines

GRPH Stock Analysis - Frequently Asked Questions

Graphite Bio, Inc. (NASDAQ:GRPH) released its quarterly earnings data on Monday, March, 20th. The company reported ($3.08) earnings per share for the quarter, topping analysts' consensus estimates of ($3.43) by $0.35.

Graphite Bio shares reverse split on Friday, March 22nd 2024. The 1-7 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Graphite Bio (GRPH) raised $224 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Graphite Bio investors own include Palantir Technologies (PLTR), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Carnival Co. & (CCL), Micron Technology (MU), PayPal (PYPL) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
3/20/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GRPH
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
$-124,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.15 per share

Miscellaneous

Free Float
35,874,000
Market Cap
$185.20 million
Optionable
Not Optionable
Beta
0.20
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:GRPH) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners